CN112351989B - 肽化合物及其治疗用途 - Google Patents

肽化合物及其治疗用途 Download PDF

Info

Publication number
CN112351989B
CN112351989B CN201980041027.6A CN201980041027A CN112351989B CN 112351989 B CN112351989 B CN 112351989B CN 201980041027 A CN201980041027 A CN 201980041027A CN 112351989 B CN112351989 B CN 112351989B
Authority
CN
China
Prior art keywords
peptide
seq
proline
amino acid
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980041027.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112351989A (zh
Inventor
艾伦·欧瓦迪亚
艾维·班-席蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Pharmaceuticals Ltd
Original Assignee
Immune Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69141375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112351989(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Pharmaceuticals Ltd filed Critical Immune Pharmaceuticals Ltd
Publication of CN112351989A publication Critical patent/CN112351989A/zh
Application granted granted Critical
Publication of CN112351989B publication Critical patent/CN112351989B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201980041027.6A 2018-07-11 2019-07-10 肽化合物及其治疗用途 Active CN112351989B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL260555 2018-07-11
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Publications (2)

Publication Number Publication Date
CN112351989A CN112351989A (zh) 2021-02-09
CN112351989B true CN112351989B (zh) 2024-03-26

Family

ID=69141375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980041027.6A Active CN112351989B (zh) 2018-07-11 2019-07-10 肽化合物及其治疗用途

Country Status (20)

Country Link
US (2) US11912790B2 (https=)
EP (2) EP3820882B1 (https=)
JP (2) JP7395517B2 (https=)
KR (1) KR102880543B1 (https=)
CN (1) CN112351989B (https=)
AU (2) AU2019300567B2 (https=)
BR (1) BR112020024748A2 (https=)
CA (1) CA3100961A1 (https=)
CO (1) CO2021001290A2 (https=)
EA (1) EA202190249A1 (https=)
ES (1) ES3026158T3 (https=)
HR (1) HRP20250746T1 (https=)
HU (1) HUE072141T2 (https=)
IL (2) IL317252A (https=)
MX (1) MX2021000264A (https=)
PL (1) PL3820882T3 (https=)
RS (1) RS66946B1 (https=)
SG (1) SG11202012773QA (https=)
WO (1) WO2020012478A2 (https=)
ZA (1) ZA202100587B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012773QA (en) 2018-07-11 2021-01-28 Immunity Pharma Ltd Peptide compounds and therapeutic uses of same
IL272074B2 (en) * 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083906A2 (en) * 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic phscn-peptide
CN101035554A (zh) * 2004-08-23 2007-09-12 维兹曼科学研究所耶达研究与发展有限公司 介导应激反应的肽抑制剂
WO2011033511A1 (en) * 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
CN104045703A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN105209492A (zh) * 2013-03-14 2015-12-30 免疫制药有限公司 抗嗜酸细胞活化趋化因子抗体在治疗炎症性肠病中的应用
CN107001442A (zh) * 2014-07-15 2017-08-01 耶路撒冷希伯来大学伊森姆研究发展公司 Cd44的分离的多肽及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
JPS4843906B1 (https=) * 1970-08-11 1973-12-21
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
EP1381839A4 (en) 2001-04-03 2005-10-12 Univ Leland Stanford Junior METHOD FOR THE IMAGE OF CELL DEOD IN VIVO
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
US20130331297A1 (en) * 2010-07-16 2013-12-12 Avantgen, Inc. Novel peptides and uses thereof
BR112013015797B1 (pt) * 2010-12-23 2021-08-31 Shell Internationale Research Maatschappij B.V. Organismo microbiano e método de produzir um derivado de acil-coa graxo
EP2715350B1 (en) * 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US8802633B1 (en) * 2013-03-18 2014-08-12 Board Of Regents, The University Of Texas System Autophagy-inducing peptide analogs
US9453061B2 (en) * 2014-08-06 2016-09-27 Brown University Method and compositions for treatment of calcineurin-related diseases
CA2988388C (en) 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
SG11202012773QA (en) 2018-07-11 2021-01-28 Immunity Pharma Ltd Peptide compounds and therapeutic uses of same
IL272074B2 (en) 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035554A (zh) * 2004-08-23 2007-09-12 维兹曼科学研究所耶达研究与发展有限公司 介导应激反应的肽抑制剂
WO2006083906A2 (en) * 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic phscn-peptide
WO2011033511A1 (en) * 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
CN105209492A (zh) * 2013-03-14 2015-12-30 免疫制药有限公司 抗嗜酸细胞活化趋化因子抗体在治疗炎症性肠病中的应用
CN104045703A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN107001442A (zh) * 2014-07-15 2017-08-01 耶路撒冷希伯来大学伊森姆研究发展公司 Cd44的分离的多肽及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Electronic interactions of i, i + 1 dithioamides: increased fluorescence quenching and evidence for n-to-p* interactions;Yun Huang等;ChemComm;第52卷(第50期);7798-7801 *
Motoyoshi Nomizu 等.Convulsant peptides related to corticotropin-releasing factor (CRF).1989,第505卷(第50期),326-328. *
unnamed protein product [Tuber aestivum];GenBank: CUS07144.1;NCBI;1-4 *

Also Published As

Publication number Publication date
AU2019300567B2 (en) 2024-09-19
KR20210045397A (ko) 2021-04-26
RS66946B1 (sr) 2025-07-31
US20240190919A1 (en) 2024-06-13
ZA202100587B (en) 2022-07-27
WO2020012478A3 (en) 2020-02-20
WO2020012478A2 (en) 2020-01-16
IL317252A (en) 2025-01-01
EA202190249A1 (ru) 2021-05-21
PL3820882T3 (pl) 2025-08-11
US20210261615A1 (en) 2021-08-26
JP2024026217A (ja) 2024-02-28
KR102880543B1 (ko) 2025-11-04
JP7395517B2 (ja) 2023-12-11
EP3820882B1 (en) 2025-04-02
EP4566617A3 (en) 2025-10-01
JP7682248B2 (ja) 2025-05-23
HUE072141T2 (hu) 2025-10-28
SG11202012773QA (en) 2021-01-28
MX2021000264A (es) 2021-05-12
IL280101B1 (en) 2025-01-01
AU2019300567A1 (en) 2021-02-25
JP2021531246A (ja) 2021-11-18
US11912790B2 (en) 2024-02-27
BR112020024748A2 (pt) 2021-03-23
ES3026158T3 (en) 2025-06-10
IL280101A (en) 2021-03-01
CN112351989A (zh) 2021-02-09
HRP20250746T1 (hr) 2025-08-15
CA3100961A1 (en) 2020-01-16
AU2024278477A1 (en) 2025-01-30
EP3820882A2 (en) 2021-05-19
IL280101B2 (en) 2025-05-01
CO2021001290A2 (es) 2021-02-26
EP4566617A2 (en) 2025-06-11
EP3820882C0 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
JP7682248B2 (ja) ペプチド化合物およびその治療的用途
PT2049562E (pt) Péptidos que possuem uma atividade farmacológica para o tratamento de distúrbios associados à migração de células alteradas, tais como o cancro
JP7809060B2 (ja) ペプチド化合物およびそれを用いる疾患の治療方法
EP4137502A1 (en) Vipr2 antagonist peptide
RU2812775C2 (ru) Пептидные соединения и их терапевтическое применение
DK1781315T3 (en) PEPTIDE INHIBITORS FOR MEDIATION OF stress responses
RU2843553C2 (ru) Пептидные соединения и их терапевтическое применение
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение
EA044784B1 (ru) Пептидные соединения и способы лечения заболеваний с их использованием

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant